CD274 and non-small cell lung carcinoma: Friedlaender et al. retrospectively analyzed the outcomes of advanced NSCLC patients with high PD‐L1 expression (>50%) treated with first‐line pembrolizumab, comparing patients with ECOG performance status 2 versus those with ECOG performance status 0–1, and showed that the median OS and progression‐free survival (PFS) were shorter in patients with ECOG performance status 2 but there was no significant difference in treatment‐related toxicity between the two groups.20